TY  - JOUR
AU  - Khoja, Lilah
AU  - Weber, Rachel Palmieri
AU  - Webb, Penelope M
AU  - Jordan, Susan J
AU  - Muthukumar, Aruna
AU  - Chang-Claude, Jenny
AU  - Fortner, Renée T
AU  - Jensen, Allan
AU  - Kjaer, Susanne K
AU  - Risch, Harvey
AU  - Doherty, Jennifer Anne
AU  - Harris, Holly R
AU  - Goodman, Marc T
AU  - Modugno, Francesmary
AU  - Moysich, Kirsten
AU  - Berchuck, Andrew
AU  - Schildkraut, Joellen M
AU  - Cramer, Daniel
AU  - Terry, Kathryn L
AU  - Anton-Culver, Hoda
AU  - Ziogas, Argyrios
AU  - Phung, Minh Tung
AU  - Hanley, Gillian E
AU  - Wu, Anna H
AU  - Mukherjee, Bhramar
AU  - McLean, Karen
AU  - Cho, Kathleen
AU  - Pike, Malcolm C
AU  - Pearce, Celeste Leigh
AU  - Lee, Alice W
TI  - Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
JO  - Gynecologic oncology
VL  - 164
IS  - 1
SN  - 0090-8258
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2021-02557
SP  - 195-201
PY  - 2022
N1  - 2022 Jan;164(1):195-201
AB  - To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95
KW  - Endometriosis (Other)
KW  - Hormone therapy (Other)
KW  - Hysterectomy (Other)
KW  - Ovarian cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34776242
DO  - DOI:10.1016/j.ygyno.2021.10.088
UR  - https://inrepo02.dkfz.de/record/177465
ER  -